
Results
16
Companies which are more than 50% undervalued based on analyst price target.
16 companies
Nanobiotix
Market Cap: €1.7b
Operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
NANO
€32.96
7D
-5.7%
1Y
655.1%
Inventiva
Market Cap: €942.8m
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
IVA
€3.99
7D
6.5%
1Y
46.4%
Valneva
Market Cap: €408.9m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
VLA
€2.16
7D
-5.0%
1Y
-19.3%
Cellectis
Market Cap: €167.7m
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
ALCLS
€2.31
7D
-9.1%
1Y
51.8%
Innate Pharma
Market Cap: €141.5m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.51
7D
-6.0%
1Y
-8.2%
Sensorion
Market Cap: €133.8m
A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
ALSEN
€0.26
7D
0%
1Y
-16.7%
OSE Immunotherapeutics
Market Cap: €75.8m
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
OSE
€3.22
7D
-2.2%
1Y
-37.6%
Adocia
Market Cap: €74.5m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€3.81
7D
1.9%
1Y
-12.7%
ABIONYX Pharma
Market Cap: €66.6m
A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.
ABNX
€1.89
7D
0.9%
1Y
50.4%
THX Pharma Société Anonyme
Market Cap: €51.0m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€3.70
7D
-6.6%
1Y
245.3%
MaaT Pharma
Market Cap: €50.5m
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
MAAT
€2.68
7D
0.2%
1Y
-38.2%
AB Science
Market Cap: €49.0m
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.
AB
€0.61
7D
-11.7%
1Y
-49.9%
Nicox
Market Cap: €32.7m
Operates as an ophthalmology company in France and internationally.
ALCOX
€0.37
7D
-6.2%
1Y
16.1%
Advicenne
Market Cap: €22.4m
A specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally.
ALDVI
€1.54
7D
-17.2%
1Y
19.8%
GenSight Biologics
Market Cap: €19.3m
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
SIGHT
€0.082
7D
0.4%
1Y
-36.8%
Valbiotis
Market Cap: €18.9m
Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.
ALVAL
€0.80
7D
0.4%
1Y
-8.6%